<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Misregulation of the canonical Wnt/β-catenin pathway and aberrant activation of Wnt signaling target genes are common in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) and contribute to <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">cancer progression</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Altered expression of human enhancer of filamentation 1 (HEF1; also known as NEDD9 or Cas-L) has been implicated in progression of <z:hpo ids='HP_0002861'>melanoma</z:hpo>, breast, and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>However, the regulation of HEF1 and the role of HEF1 in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> <z:mp ids='MP_0002006'>tumorigenesis</z:mp> are not fully understood </plain></SENT>
<SENT sid="3" pm="."><plain>We here identify HEF1 as a novel Wnt signaling target </plain></SENT>
<SENT sid="4" pm="."><plain>The expression of HEF1 was upregulated by Wnt-3a, β-catenin, and Dvl2 in a dose-dependent manner, and was suppressed following β-catenin downregulation by shRNA </plain></SENT>
<SENT sid="5" pm="."><plain>In addition, elevated HEF1 <z:chebi fb="2" ids="33699">mRNA</z:chebi> and protein levels were observed in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell lines and <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumor</z:e> tissues, as well as in the colon and <z:mpath ids='MPATH_270'>adenoma</z:mpath> <z:mpath ids='MPATH_491'>polyps</z:mpath> of Apc(Min/+) mice </plain></SENT>
<SENT sid="6" pm="."><plain>Moreover, HEF1 levels in human <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumor</z:e> tissues increased with the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> grade </plain></SENT>
<SENT sid="7" pm="."><plain>Chromatin immunoprecipitation (ChIP) assays and promoter analyses revealed three functional T-cell factor (TCF)-binding sites in the promoter of HEF1 responsible for HEF1 induction by Wnt signaling </plain></SENT>
<SENT sid="8" pm="."><plain>Ectopic expression of HEF1 <z:mp ids='MP_0000351'>increased cell proliferation</z:mp> and colony formation, while downregulation of HEF1 in SW480 cells by shRNA had the opposite effects and inhibited the xenograft <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Furthermore, overexpression of HEF1 in SW480 cells promoted cell migration and invasion </plain></SENT>
<SENT sid="10" pm="."><plain>Together, our results determined a novel role of HEF1 as a mediator of the canonical Wnt/β-catenin signaling pathway for cell proliferation, migration, and <z:mp ids='MP_0002006'>tumorigenesis</z:mp>, as well as an important player in colorectal <z:mp ids='MP_0002006'>tumorigenesis</z:mp> and progression </plain></SENT>
<SENT sid="11" pm="."><plain>HEF1 may represent an attractive candidate for drug targeting in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
</text></document>